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ABSTRACT:  
Objective: Since pattern-recognition receptors (PRRs) in particular Toll-like receptors were 
found to be over-expressed in the synovium of rheumatoid arthritis (RA) patients and to play 
a role in the production of disease relevant molecules, we analyzed the expression, regulation 
and function of the PRR NOD2 in RA. 
Methods: Expression of NOD2 in synovial tissues was analyzed by immunohistochemistry. 
Expression and induction of NOD2 in RASFs was measured by conventional and Real-time 
PCR. Levels of IL-6 and IL-8 were measured by ELISA, expression of MMPs by ELISA 
and/or Real-time PCR. The expression of NOD2 was silenced with siRNA. Western blots 
with antibodies against phosphorylated and total p38, JNK and ERK, and inhibitors of p38, 
JNK and ERK were applied. Activation of NF-κB was measured by EMSA. 
Results: NOD2 was expressed by fibroblasts and macrophages in the synovium of RA 
patients, predominantly at sites of invasion into articular cartilage. In cultured RASFs no basal 
expression of mRNA for NOD2 was detectable, but was induced by polyI-C, LPS and TNF. 
After upregulation of NOD2 by TLR ligands, its ligand MDP increased the expression of IL-6 
and IL-8 via p38 and NF-κB. Stimulation with MDP further induced the expression of 
MMP1, MMP3 and MMP13. 
Conclusion: Not only TLRs but also the PRR NOD2 is expressed in the synovium of RA 
patients and activation of NOD2 synergistically acts with TLRs in the production of 
proinflammatory and destructive mediators. Therefore NOD2 might contribute to the 
initiation and perpetuation of chronic, destructive inflammation in RA. 
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 Activation of the innate immune system is characterized by the detection of pathogens 
via pattern recognition receptors (PRRs) triggering an inflammatory response. In general, the 
advancement of this cascade of pro-inflammatory factors leads to clearance of the invading 
pathogen followed by dissolution of the inflammation. However, growing knowledge of 
implicated signaling pathways give evidence for more intricate mechanisms involved in 
physiological as well as pathological activation of innate immunity. The discovery of 
endogenous ligands for most of the PRRs lead to the hypothesis that in addition to exogenous 
pathogens, PRRs might response to damaged tissue and parts of apoptotic-cell debris. 
Furthermore, activation of PRRs has been found to modulate adaptive immune responses 
through the regulation of co-stimulatory molecules, maturation of dendritic cells and 
stimulation of B-cells (1, 2). Thus, it is feasible to assume that activation of innate immune 
receptors has a role in triggering autoimmune diseases such as rheumatoid arthritis (RA). 
 The family of PRRs comprises membrane-bound receptors such as the well-
characterized Toll-like receptors (TLRs) and cytoplasmic receptors like the more recently 
discovered group of nucleotide-binding domain and LRR receptors (NLRs). NLRs have 
similarities to TLRs in regard to their leucine-rich-repeat (LRR) domain mediating ligand 
binding. Their ligands, structure and signaling pathways however differ. There are two major 
subfamilies of NLRs, NODs and NALPs. NOD1 recognizes products from Gram-negative 
bacteria (diaminopimelic acids), while NOD2 senses murayml dipeptide (MDP), a 
peptidoglycan derived peptide from Gram-negative as well as Gram-positive bacteria. Up to 
now, NODs have mainly been described on antigen-presenting cells and epithelial cells of the 
intestines (3-5). After binding of their ligands, NOD receptors signal by recruiting the serine 
threonine kinase RICK, also called RIP2, which then in turn activates TAK1. Further 
downstream, NOD signaling was shown to lead to activation of NFκB and mitogen activated 
kinases (MAPKs) (6). 
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 The active role of synovial fibroblasts in inflammation and joint destruction during the 
course of RA has been documented in a variety of studies (7). Synovial fibroblasts from RA 
patients (RASFs) express functional TLR2, TLR3 and TLR4, the activation of which leads to 
secretion of pro-inflammatory cytokines, chemokines and matrix degrading enzymes (8-10). 
Therefore, RASFs emerge as cells of the innate immune system which might take part in the 
initiation and perpetuation of the chronic, destructive inflammation in RA. 
 In the current study, we show the expression of the PRR NOD2 in the synovium of 
RA patients and explore its induction, signaling pathways and functionality in RASFs. 
 
MATERIAL AND METHODS 
 Patients and tissue preparation: Synovial tissues from patients with RA and 
osteoarthritis (OA) were collected after written consent during joint replacement surgery 
(Schulthess Clinic Zurich, Switzerland). All RA patients fulfilled the American College of 
Rheumatology criteria for the classification of RA. For immunohistochemistry, synovial 
tissues were fixed in formalin and embedded in paraffin. For cell culture, synovial fibroblasts 
were isolated and cultured as described before (11). Cultured synovial fibroblasts were used 
for experiments after 4 to 9 passages. 
 Immunohistochemistry: After deparaffinization, sections were washed in phosphate 
buffered saline (PBS) and treated with 1% H2O2 to disrupt endogenous peroxidase activitiy. 
Unspecific protein binding was blocked with 1% bovine serum albumin (BSA)/5% goat 
serum for one hour. Polyclonal rabbit anti-NOD2 antibodies (Abcam, Cambrige, UK) or 
normal rabbit serum were applied (1:4000 in 1% BSA) for 1h at room temperature. Slides 
were washed in PBS/0.05% Tween® and incubated with biotinylated goat anti-rabbit 
antibodies (Jackson ImmunoResearch, Suffolk, UK) for 30 min. The signal was amplified 
with horseradish-peroxidase (HRP)-conjugated streptavidin (Vectastain Elite ABC kit, Vector 
laboratories, Burlingame, CA). Sections were developed with aminoethylcarbazole 
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chromogen and counterstained with hematoxylin. To show specificity of the rabbit anti-
human antibodies, pre-incubation of the antibodies  with a synthetic peptide, corresponding to 
14 amino acids of NOD2 (Abcam, Cambridge, UK) was performed (30 min, 37°) and staining 
procedures were continued as described above. Simultaneous NOD2/CD68 and 
NOD2/vimentin double staining was performed using the NOD2 staining protocol as 
described above together with mouse anti-CD68 or mouse anti-vimentin primary antibodies. 
Alkaline-phosphatase (AP) conjugated goat anti-mouse antibodies were applied (Jackson 
ImmunoResearch, Suffolk, UK). BCIP/NBT was used as substrate for AP, NovaRed as 
substrate for HRP. Slides were counterstained with methyl green (all Vector laboratories, 
Burlingame, CA) 
 Stimulation experiments: Synovial fibroblasts were stimulated with the following 
reagents: 10 ng/ml TNFα, 1 ng/ml IL-1β (both R&D Systems, Minneapolis, MN), 300 ng/ml 
bacterial lipopeptide (bLP) palmitoyl-3-cysteine-serine-lysine-4, 10 µg/ml polyI-C (PIC) 
(both InvivoGen, San Diego, CA),  100 ng/ml lipopolysaccaride (LPS) from Escherichia coli 
(List Biological Laboratories, Campbell, CA), 100U/ml IFNβ (R&D Systems, Minneapolis, 
MN) and/or 10 µg/ml muramyl dipeptide (MDP) N-Acetylmuramyl-L-alanyl-D-isoglutamine 
hydrate (Sigma, Basel, Switzerland). SB203580 (Calbiochem, San Diego, CA) and SP600125 
(Merck, Darmstadt, Germany) were used at 10µM, PD98059 (Calbiochem, San Diego, CA)  
at 25µM.  
 Conventional PCR: Total RNA was isolated using the RNeasy MiniPrep kit (Qiagen, 
Basel, Switzerland) including DNase treatment. RNA was reverse transcribed and NOD2 
transcripts were amplified using primers spanning a 317bp fragment (forward primer: 
GAATGTTGGGCACCTCAAGT; reverse primer: CAAGGAGCTTAGCCATGGAG). 
Reaction products were separated on a 1% agarose gel and signals were visualized using 
ethidium bromide.  
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 Enzyme linked immunosorbant assay (ELISA): Levels of IL-6 and IL-8 in cell 
culture supernatants were quantified using OptEIA kits (BD Pharmingen, San Diego, CA). 
Levels of MMP3 were determined with a DuoSet ELISA Development kit (R&D Systems, 
Minneapolis, MN) according to the manufacturer’s protocol. 
 siRNA: Commercially available siRNA against NOD2 (Santa Cruz Biotechnoligy, 
Santa Cruz, CA) or scrambled RNA control reagent (Ambion, Austin, TX) were transfected 
by nucleofection at a concentration of 50pmols/5 x 105 cells using the Basic Nucleofector® 
Kit for primary mammalian fibroblasts (Amaxa, Cologne, Germany). 
 Electrophoretic Mobility-Shift Assay (EMSA): Nuclear extracts were prepared 
using a nuclear/cytosol fractionation kit (Biovision, Mountain View, CA).  The binding of 
NF-κB to DNA after MDP stimulation was visualized with an Electrophoretic Mobility Shift 
Assay (Panomics, Redwood City, CA). Specificity of the complex was confirmed by adding 
cold probe and 1 µg mouse anti-human NFκB p65 antibodies (Santa Cruz Biotechnology, 
Santa Cruz, CA) respectively. 
 Western blot: Cells were lysed in 2x Laemmli buffer, and proteins were denaturated 
by incubation at 95°C for 3min. Samples were applied to SDS-PAGE and elektroblotted onto 
Protran nitrocellulose transfer membranes (Schleicher & Schüll, Dassel, Germany). After 
blocking with 5% non-fat dry milk, membranes were incubated with rabbit anti-human 
antibodies directed against NOD2 (Santa Cruz Biotechnology, Santa Cruz, CA), or against 
phosphorylated sites of p38, JNK or ERK (all Cell Signaling Technology, Danvers, MA). As 
secondary reagents HRP-conjugated goat anti-rabbit antibodies (Jackson ImmunoResearch, 
West Grove, PA) were used, and signals were visualized by enhanced chemoluminescence 
system (Amersham Biosciences, Otelfingen, Switzerland). For normalization, membranes 
were stripped and probed with mouse anti-human α-tubulin (Sigma, Basel, Switzerland) or 
rabbit anti-human p38, ERK or JNK antibodies (Cell Signaling Technology, Danvers, MA). 
The intensity of the signal was measured by densitometric measurements. 
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 Real-time PCR: Total RNA was isolated using the RNeasy MiniPrep kit (Qiagen, 
Basel, Switzerland) including DNase treatment, reverse transcribed and used for relative 
quantification of mRNA levels by Taqman/SYBR green Real-time PCR using eukaryotic 18S 
rRNA as endogenous control (Applied Biosystems, Rotkreuz, Switzerland).  
NOD2: forward TTC TCC GGG TTG TGA AAT GT; reverse CTC CTC TGT GCC TGA  
AAA GC; MMP1: forward TGT GGA CCA TGC CAT TGA GA; reverse TCT GCT TGA 
CCC TCA GAG ACC; probe AGC CTT CCA ACT CTG GAG TAA TGT CAC ACC; 
MMP3: forward GGG CCA TCA GAG GAA ATG AG; reverse CAC GGT TGG AGG GAA 
ACC TA; probe AGC TGG ATA CCC AAG AGG CAT CCA CAC; MMP9: forward GGC 
CAC TAC TGT GCC TTT GAG; reverse  GAT GGC GTC GAA GAT GTT CAC; probe 
TTG CAG GCA TCG TCC ACC GG; MMP13: forward TCC TAC AAA TCT CGC GGG 
AAT; reverse GCA TTT CTC GGA GCC TCT CA; probe CAT GGA GCT TGC TGC ATT 
CTC CTT CAG; MMP14: forward TGG AGG AGA CAC CCA CTT TGA ; reverse GCC 
ACC AGG AAG ATG TCA TTT C ; probe CCT GAC AGT CCA AGG CTC GGC AGA. 
 Statistical analysis: Values are presented as mean ± SEM. Wilcoxon signed rank test 
or Mann-Whitney U test was applied to analyze results for significant differences (p<0.05) 
using GraphPad Prism Software. 
 
RESULTS 
 Expression of NOD2 in the synovium of RA and OA patients. 
Immunohistochemical staining of synovial tissues showed clear expression of NOD2 in 9 out 
of 11 RA patients, but only in 1 out of 7 OA patients (Figure 1A-D). NOD2 in RA synovial 
tissues was mainly localized at sites of cartilage and bone destruction, sporadically NOD2 
was also found in the lining and sublining layers. Lymphocytic infiltrates or blood vessels did 
not stain with anti-NOD2 antibodies. Double stainings with NOD2 and CD68 or vimentin, 
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showed that NOD2 is expressed by both, macrophages as well as by fibroblasts (Figure 
2A,B).  
 Expression and induction of  NOD2 in synovial fibroblasts. To analyse whether 
NOD2 is produced by fibroblasts in vitro and how its expression can be induced, we 
stimulated cultured synovial fibroblasts with the pro-inflammatory cytokines TNFα and IL-1, 
and with the TLR2 ligand bLP, the TLR3 ligand PIC and the TLR4 ligand LPS. Levels of 
TNFα and IL-1 are high in patients with RA and these two cytokines have been shown to 
induce expression of a variety of pro-inflammatory mediators in RA (12). TLR2, TLR3 and 
TLR4 are the most abundantly expressed TLRs on RASF. Stimulation with the respective 
ligands was shown to induce the expression of chemokines, cytokines and matrix degrading 
enzymes (10, 13). After conducting conventional PCR, we found that synovial fibroblasts 
didn’t express mRNA for NOD2 constitutively. However, its transcription could be induced 
by all used stimuli (Figure 3A). To see differences in the induction of NOD2 mRNA between 
RASFs and OASFs, mRNA levels after stimulation were quantified by Real-time PCR. 
Hereby, a stronger induction of NOD2 transcription in RASFs compared to OASFs was 
visible (Figure 3B). In the analyzed cultures, only after stimulation with PIC this difference 
between RASF and OASF was constant and therefore statistically significant. Since PIC and 
LPS both result in activation of the TRIF pathway and production of type I interferons (IFN), 
we measured whether maybe IFNβ might be responsible for the induction of NOD2. 
However, mRNA levels of NOD2 were not induced after stimulation of RASF with 100U/ml 
IFNβ (data not shown). Increased levels of NOD2 were also seen on protein level by 
incubation of RASFs with TNF, IL-1, bLP, PIC or LPS for 48h (Figure 3C). 
 Production of cytokines after stimulation with MDP. To test the functionality of 
NOD2 receptors on synovial fibroblasts, RASFs were stimulated with TNFα, IL-1, bLP, PIC 
or LPS alone or in combination with the NOD2 ligand MDP for 24h. Levels of IL-6 and IL-8 
were measured in the supernatants by ELISA. Since no constitutive expression of the receptor 
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NOD2 has been measured on RASFs, MDP alone had no effect on the production of IL-6 or 
IL-8, as expected. When MDP was added in combination with the stimuli that had induced the 
expression of NOD2, namely TNFα, IL-1, bLP, PIC and LPS, RASFs produced higher 
amounts of IL-6 and IL-8 than with the mentioned stimuli alone (Figure 4A, B). The increase 
in IL-6 and IL-8 production after addition of MDP was significant for all tested stimuli, 
except for IL-6 levels after stimulation with IL-1 and MDP. The same experiments done with 
OASFs lead to similar results (data not shown).  
 In the next experiment, RASFs were stimulated with PIC for 5h to induce the 
expression of NOD2, washed with PBS and then incubated with increasing concentrations of 
MDP for 24h. Measurements of IL-6 and IL-8 in the supernatants indicated a dose-dependent 
and significant increase in the levels of these cytokines by stimulation with MDP (Figure 4C).  
 Further confirmation that NOD2 signaling regulates the production of IL-6 and IL-8 
was obtained by specific downregulation of  NOD2 by siRNA. 48h after transfection of 
RASFs with NOD2 targeted siRNA or scrambled siRNA, using the same stimulation scheme 
as mentioned above (5h PIC pre-stimulation, 24h MDP stimulation), IL-6 levels were reduced 
by 22% (48.3 ± 15.9 pg/ml vs 37.5 ± 15 pg/ml) and IL-8 levels by 25% (67.6 ± 26.1 pg/ml vs 
50.9 ± 22.8 pg/ml) (Figure 4D). The mean expression of NOD2 mRNA in silenced cells was 
60% less than in cells transfected with control RNA as measured by Real-time PCR. 
 NOD2 signaling pathways. To elucidate the signaling pathways that are activated by 
the binding of MDP to NOD2, we first analyzed members of the mitogen-activated protein 
kinase (MAPK) pathway by performing Western blots with protein samples from RASFs that 
were stimulated for 5h with PIC followed by 15, 30, or 60 min stimulation with MDP. 
Whereas the ratio between phosphorylated/total protein only slightly increased in the case of  
c-jun N-terminal kinase (JNK) and extracellular-signal regulated kinase (ERK), 
phosphorylation of p38 after MDP stimulation was clearly visible (Figure 5A). 
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 In accordance with the results from the Western blots, addition of the p38 inhibitor 
SB203580 to 24h MDP stimulation (5h PIC pre-stimulation) almost completely blocked IL-6 
and IL-8 production, whereas the ERK inhibitor PD98059 or the JNK inhibitor SP600125 had 
little or no effect (Figure 5B).  
 In addition to p38 MAPK activation, MDP stimulation after 5h PIC pre-stimulation 
lead to increased binding of NF-κB to its DNA binding sites as shown by EMSA (Figure 5C). 
 Production of matrix-metalloproteinases (MMPs) after stimulation with MDP. 
Since RASFs also contribute to pathological matrix degradation by secretion of MMPs, we 
analyzed whether stimulation with MDP modulates the expression of MMPs. Levels of 
MMP1, MMP3, MMP9, MMP13 and MMP14 mRNA were measured in RASFs stimulated 
with PIC alone or in combination with MDP. Levels of MMP9 and MMP14 mRNA did not 
change after addition of MDP, while levels of MMP1, MMP3 and MMP13 were significantly 
increased when MDP was added (Figure 6A). Stimulation of MMP3 secretion by MDP was 
verified on the protein level with ELISA (Figure 6B). Furthermore, silencing of NOD2 by 
siRNA lead to significant reduction of mRNA expression for MMP1, MMP3 and MMP13 
after pre-stimulation with PIC for 5h and subsequent 24h stimulation with MDP in RASFs 
(Figure 6C).  
 
DISCUSSION: 
 In the present work, we show elevated expression of the pattern-recognition receptor 
NOD2 in the synovium of RA patients. Furthermore, we provide evidence that NOD2 
activation in synovial fibroblasts leads to the expression of pro-inflammatory cytokines and 
matrix-degrading enzymes via MAPK and NF-κB signaling pathways. 
 Up to now expression of NOD2 has mainly been analyzed in the context of Crohn’s 
disease, since a polymorphisms in the gene encoding NOD2, CARD15, was found to be 
correlated with higher susceptibility to develop this inflammatory bowel disease in 
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Caucasians (14). In this respect NOD2 expression has been shown in intestinal mononuclear 
and endothelial cells and in Paneth cells (4, 15, 16). Furthermore, expression of NOD2 was 
found in oral epithelial cells and fibroblasts, osteoblasts and trophoblast cells (17-20). These 
studies, including our work point to the fact that resident tissue cells are able to express innate 
immune receptors and take an active role in the recognition and response to invading 
pathogens. The high expression of NOD2 in RA, along with previously shown increased 
expression of TLR2, TLR3 and TLR4 underscores the importance of activation of innate 
immune mechanisms in RA (21). However, endogenous ligands such as RNA from necrotic 
cells for TLR3 or fibrin for TLR4, have yet to be found for NOD2 (10, 22). Nevertheless it is 
feasible to assume that in the pathogenesis of RA an initial infection or certain bacterial/viral 
components lead to activation of innate immune receptors which provokes an inflammatory 
reaction. Due to the inflammation, endogenous ligands, so called DAMPs (danger associated 
molecular pattern molecules) get released from the tissue and further stimulate innate immune 
reactions in an positive feedback mechanism. In this respect, our data clearly shows that 
activation of TLRs leads to increased expression of NOD2. Thereby the repertoire of immune 
receptors in the cell is widened, making it more sensitive to react to invading pathogens 
and/or endogenous danger signals. 
 A central role of synovial fibroblasts in this inflammatory activation is suggested by 
their production of a wide panel of chemokines, pro-inflammatory cytokines and matrix-
degrading enzymes after stimulation of PRRs as shown in the current study and in others (9, 
10). This finding assigns different functions to synovial fibroblasts than to epithelial cells, 
where no production of pro-inflammatory cytokines after stimulation of PRRs was found (23). 
Most interestingly, cultured synovial fibroblasts from RA patients appear to response even 
stronger to activation compared to synovial fibroblasts from OA patients, as we show here for 
the expression of NOD2. This phenomenon was previously shown for a variety of  molecules 
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and was ascribed to an intrinsic, inflammation-independent activated phenotype of these cells 
(7). 
 The induction of pro-inflammatory cytokines by NOD2 signaling has been shown 
before and a synergistic effect of NODs and TLRs has been suggested (24-26). Since TLR 
activation readily induced NOD expression and, after induction of NOD2, MDP alone could 
induce IL-6 and IL-8, we think that the synergistic effect in synovial fibroblasts is mainly 
based on the up-regulation of NOD2 receptor by TLR ligands. On the other hand, MDP 
stimulation had no influence on the expression of TLR2, TLR3 or TLR4 on synovial 
fibroblasts (data not shown).  
 Regarding NOD2 signaling pathways, we could show that NOD2 stimulation in 
synovial fibroblasts leads to the activation of NF-κB as well as of MAPK, in particular p38. 
NF-κB activation by MDP has been previously shown and failure of activation of this 
pathway due to NOD2 mutations has been linked to the pathogenesis of Crohn’s disease (27). 
The activation of MAPK via NOD2 has been shown in murine macrophages, where p38, ERK 
and JNK were phosphorylated after stimulation with MDP (6, 28). In synovial fibroblasts we 
mainly found p38 MAPK to be activated by MDP/NOD2. However, indirect mechanisms for 
the observed increase in MAPK phosphorylation can not completely be ruled out by this 
experiment. Regarding the strong inhibition of IL-6/IL-8 production by SB203580, it has to 
be taken into account that SB203580 has been shown not only to inhibit p38 but also the 
signaling molecule RICK, also called Rip2. Since RICK has a key role in transferring signals 
after engagement of MDP to NOD2, its inhibition surely has an influence on cytokine 
production after MDP stimulation (29).  
 Taken together, our study gives evidence that in addition to TLRs, other PRRs are 
expressed in RA and that their activation on synovial fibroblasts, possibly by yet unknown 
endogenous ligands, might lead to perpetuation of inflammation and matrix destruction.  
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FIGURE LEGENDS 
Figure 1. Expression of NOD2 in RA and OA synovial tissues. Representative pictures of 
immunhistochemical staining of NOD2 in A) RA (n=11) and C) OA (n=7) synovial tissues. 
B) RA tissue isotype control, insert showing lack of staining after incubation with a NOD2 
blocking peptide; D) OA tissue isotype control. Pre-incubation of the antibodies with a 
synthetic NOD2 peptide blocked staining by rabbit anti-human NOD2 antibodies as shown in 
inserts of A and B.  Magnification 100x, positive signals appear in red, nuclei were 
counterstained with hematoxylin.  
 
Figure 2. NOD2 is expressed in fibroblasts and macrophages in the synovium. 
Representative pictures of immunhistochemical double staining of RA synovial tissues  (n=4) 
with NOD2 (red signal) and A) CD68 (blue signal), and B) vimentin (blue signal). 
Magnification 100x, magnification in inserts 630x. Nuclei were counterstained with methyl 
green.  
 
Figure 3. Expression of NOD2 in RASFs is up-regulated by pro-inflammatory cytokines 
and TLR ligands. A) Expression of NOD2 mRNA in RASFs after incubation with various 
stimuli as measured by conventional PCR. One representative picture of 2 experiments is 
shown. B) Differential induction of NOD2 mRNA in RASFs (n=6) compared to OASFs (n=4) 
after incubation with various stimuli as measured by Real-time PCR. Differences between 
patient groups were calculated by Mann-Whitney U test, data are presented as mean ± SEM. 
C) Western blot showing increased levels of NOD2 protein after stimulation of RASFs for 
48h (n=3, one representative blot shown). 
 
Figure 4. Levels of IL-6 and IL-8 are up-regulated after stimulation of RASFs with 
MDP. Protein levels of A) IL-6 and B) IL-8 in supernatants of RASFs (n=7) stimulated with 
 17
TNF, IL-1 or TLR ligands alone (stim), or in combination with MDP (stim + MDP). C) 
RASFs (n=6) were stimulated with PIC for 5h, washed and then stimulated with increasing 
concentrations of MDP for 24h. Levels of IL-6 and IL-8 in the supernatants were measured by 
ELISA. D) Scrambled or NOD2 siRNA transfected RASFs (n=6) were stimulated with PIC 
for 5h, washed and then stimulated with MDP for 24h. Levels of IL-6 and IL-8 in the 
supernatants were measured by ELISA. Significant differences were calculated by Wilcoxon 
signed rank test, all data are presented as mean ± SEM. 
 
Figure 5. MDP signals via p38 and NF-κB. A) RASFs (n=2) were stimulated with PIC for 
5h, washed and then stimulated with MDP for 15, 30, or 60min. Levels of phosporylated and 
total p38, JNK and ERK were measured by Western blot and quantified by densitometric 
measurements. B) RASFs were stimulated with PIC for 5h, washed and then stimulated with 
MDP with or without addition of a pharmacological inhibitor of p38, ERK or JNK for 24h. 
Levels of IL-6 (n=5) and IL-8 (n=6) were measured by ELISA. C) Nuclear extracts from 
RASFs stimulated with PIC for 5h, washed and then stimulated with MDP for 30 and 60 min 
were used in an EMSA with a biotin- labeled NF-κB probe and an unlabelled (cold) probe to 
exclude unspecific binding. 
 
Figure 6. Stimulation with MDP induces the expression of MMP1, MMP3 and MMP13 
in RASFs. A) RASFs (n=6) were stimulated with MDP and/or PIC and changes in mRNA 
expression of MMP1, MMP3, and MMP13 were measured by Real-time PCR. B) Total 
amount of MMP3 protein in the supernatants of unstimulated RASFs and RASFs stimulated 
with MDP and/or PIC (n=10) as measured by ELISA.. C) Levels of MMP1, MMP3 and 
MMP13 mRNA were significantly diminished after 5h pre-stimulation with PIC and 24h 
stimulation with MDP in NOD2 silenced RASFs when compared to control transfected 
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RASFs (n=7). Significant differences were calculated by Wilcoxon signed rank test, all data 
are presented as mean ± SEM 
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